COVID-19

Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities

PRESS RELEASE - REGULATED INFORMATION 30 June 2023, 7:00 CEST Disclosure of Outstanding Voting Securities Mechelen, Belgium, 30 June 2023…

1 year ago

FDA Grants De Novo Marketing Authorization for KidneyIntelX.dkd to Assess Risk of Progressive Kidney Function Decline in Adults with Diabetes and Early-Stage Kidney Disease

Simple Blood Test Aids Risk Assessment for Approximately 14 Million Eligible Patients in the United States Diabetic Kidney Disease is the…

1 year ago

Bionano Announces the Stratys™ System for OGM and VIA™ Software for Hematologic Malignancies

The Stratys™ instrument for optical genome mapping (OGM) will enable a four-fold increase in raw data generation rate compared to…

1 year ago

Advanced Health Intelligence Ltd Announces Implementation of ADS Ratio Change

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Advanced Health Intelligence Ltd (ASX/NASDAQ:AHI) (“Advanced Health Intelligence”, “AHI” or the “Company”)…

1 year ago

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company…

1 year ago

Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer

SAN FRANCISCO, June 29, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni…

1 year ago

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of…

1 year ago

BioSig Joins Webull Corporate Connect

Webull’s investor community can now access real-time BioSig investor communications and Q&AWestport, CT, June 29, 2023 (GLOBE NEWSWIRE) -- BioSig…

1 year ago

NeuBase Presents Non-Human Primate Data Illustrating Stealth Editors™ are Non-Immunogenic, Opening the Door to Redosing

New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide…

1 year ago

Microbot Medical Successfully Completes an Extensive Pre-Clinical Study Performed in the US

The study was conducted over two days by a team of global key opinion leaders and with participation of executives…

1 year ago